Scientific Publications
“Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-Like Kinase 1 (MLN0905).” J. Med. Chem. 2012, 55, 197.
“MLN0905, a small-molecule PLK1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma.” Mol. Cancer Ther. 2012, 11, 2045.
“Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors.” J. Med. Chem. 2011, 54, 1836.
“Discovery and optimization of pyrazoline compounds as B-Raf inhibitors.” Bioorg. Med. Chem. Lett. 2010, 20, 4800.
“Discovery and optimization of N-acyl and N-aroylpyrazolines as B-Raf kinase inhibitors.” Bioorg. Med. Chem. Lett. 2010, 20, 4795.
“Total syntheses of the assigned structures of Lituarines B and C.” J. Am. Chem. Soc. 2008, 130, 422.
“Diversity-Oriented synthesis of polyketide natural products via iterative chemo- and stereoselective functionalization of polyenoates: development of a unified approach for the C(1-19) segments of Lituarines A-C” Org. Lett. 2005, 7, 139.
“Bifunctional molecular linchpins: A three-component coupling protocol employing 2-bromoallyltrimethylsilane.” Synlett 2004, 16, 1363.
“Enantioselective synthesis of Borrelidin.” J. Am. Chem. Soc. 2003, 125, 1459.
“Enantio- and diastereoselective reductive aldol reactions with iridium-Pybox catalysts.” Org. Lett. 2001, 3, 1829.
“Rhodium-catalyzed enantioselective reductive aldol reaction.” J. Am. Chem. Soc. 2000, 122, 4528.
“Simple metal alkoxides as effective catalysts for the hetero-aldol-Tishchenko reaction.” Org. Lett. 1999, 1, 1427.